Staphylococcus aureus is a common cause of community and hospital-acquired infections. Moreover, the clinical impact of S. aureus is on the rise because of the global increase in the incidence of multidrug-resistant strains and its growing prevalence as a major cause of surgical infections. As a result, there is a pressing need to identify new antistaphylococcal agents and preventative strategies that will help in the management of these types of infections. This report describes the successful use of a probiotic, Lactobacillus fermentum RC-14, and its secreted biosurfactant to inhibit surgical implant infections caused by S. aureus. L. fermentum RC-14 and its secreted biosurfactant both significantly inhibited S. aureus infection and bacteria adherence to surgical implants.